ClinicalTrials.gg
Enrolling by invitationNCT06938217Updated Apr 22, 2025

Safety and Efficacy of Low-Flow ECMO in a Multi-modal Cohort of Adults in Respiratory Failure

An interventional study of Low-flow ECMO in Acute Hypoxemic Respiratory Failure, Mechanical Ventilation and Acute Respiratory Distress Syndrome (ARDS), sponsored by Institute for Extracorporeal Life Support. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-04-22.

Sponsored by Institute for Extracorporeal Life Support · Not applicable, Interventional, and Device feasibility

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 349 studies in Respiratory Insufficiency with a site in United States — 44 open to participants now, 60 under way, 1 of them phase 3. Respiratory Insufficiency · United States.

Planned enrollment
147th of 253
30 · median 42
Started
2025
with 3 others
No phase
159 of 349
30 open now
Primary completion
2026-12
later than 22 of 59 live
Registered
328th of 349
by date

Among the 349 studies in Respiratory Insufficiency with a site in United States, this one is the 147th largest by planned enrollment of the 253 interventional ones that give a count, is one of 4 that started in 2025, is one of 159 with no phase, reaches primary completion later than 22 of the 59 other live ones, and was the 328th registered.

Respiratory Insufficiency

1,371 studies on the registry are indexed under Respiratory Insufficiency; 266 are open to participants now.

Browse Respiratory Insufficiency studies →

Open to participants now

44 of the 349 studies in Respiratory Insufficiency with a site in United States are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 349 studies in Respiratory Insufficiency with a site in United States, or all of them as a file.
02

Study summary

The current standard of care (SOC) for treatment of patients with acute respiratory distress syndrome (ARDS), inhalation injury, volume overload, and/or pulmonary dysfunction is mechanical ventilation (MV). However, these techniques are associated with several complications after prolonged use, including risk of infection, increased sedation requirements, pulmonary edema, ventilator-induced lung injury (VILI), barotrauma, and multi-organ failure.

Extracorporeal life support (ECLS) has been used to successfully minimize, replace, or avoid the use of MV. This concept is critical as it permits ultra-lung protective MV settings, mobilization, early ambulation of patients, and timely extubation (when appropriate).

Conventional ECLS typically requires blood flows of 3-6 L/min, and its cannula sizes range from 21-25 Fr. This is by definition "high-flow" as it constitutes near-complete extracorporeal circulation of patient's circulating blood volume. On the other hand, low-flow ECLS at 1-2.5 L/min has been shown to prevent deleterious shifts in pH and PaCO2 at a lower level of invasiveness, and its cannula sizes range from 19-20 Fr dual lumen cannulas (which are associated with less serial dilation). The investigators propose the use of a low-flow circuit to include the NovaLung system in conjunction with a smaller tubing set and cannula to enable earlier utilization of ECLS with less invasiveness and smaller catheters. Specifically, the study will either utilize the Crescent RA cannula (or equivalent dual-lumen cannula) or use a 15-25 Fr cannula, both with 3/8 tubing/step-down tubing, as needed, for our study. A femoral (fem)-femoral or femoral-internal jugular (IJ) approach may also be used.

Carbon dioxide is six times more diffusible than oxygen across the membrane; thus, carbon dioxide transfers can occur with high efficiency at our targeted blood flows of 1-2.5L/min. Oxygen can still transfer at these blood flows, and low flow can improve oxygen levels to some degree.

There are three benchtop-based manuscripts that suggest that low-flow ECMO is associated with a potential increase in factors that increase the risk of bleeding complications/circuit changes. However, the manuscripts either tested \<1 L/min blood flow rates, or the effect of cannula size was not considered. None of them included the biological component of endothelial interaction. Mitigating the risk of bleeding complications by will be completed by administering anticoagulants with a target PTT of 40-50 seconds, and by monitoring the patients and their coagulation panels closely. There may be less risk of circuit clotting in our study because of chosen flow rates (1-2.5 L/min).

Read the detailed description

The investigators focus is to demonstrate the safety, feasibility, and efficacy of low-flow ECLS as a treatment for multiple respiratory conditions (including ARDS, volume overload, obstructive and restrictive pulmonary diseases, hypoxia) in conjunction with MV.

BACKGROUND

The two most significant trials in the last five years investigating strategies around low-flow ECLS with the intent of CO2 reduction/ventilator reduction are as follows:

  • SUPERNOVA Multi-Center Phase II Study in Europe and Canada: In 2019 Combes et al assessed the feasibility and safety of lower CO2 extraction ECLS devices (300-500 mL/min) in patients with moderate ARDS compared to higher CO2 extraction ECLS devices (800-1000 mL/min, N=95). The authors concluded that the use of low-flow ECLS to facilitate ultra-protective ventilation was feasible, and that it mitigated respiratory acidosis in patients with moderate ARDS.
  • REST Multi-Center Randomized Clinical Trial (RCT) in the United Kingdom: In 2021 McNamee et al set to determine whether lower tidal volume MV using extracorporeal CO2 removal improves outcomes in adult patients with acute hypoxemia respiratory failure (n=202) compared to conventional low tidal volume MV (n=210). There were significantly fewer mean ventilator-free days in the extracorporeal CO2 removal group compared with the SOC (p=0.02). However, the trial was halted because of futility and feasibility. Although the conclusion was that the use of extracorporeal CO2 removal did not significantly reduce 90-day mortality (p=0.68), the study may have been underpowered to detect an important difference. Furthermore, the most notable limitation of the study was that the duration of low-flow ECLS was limited to less than 7 days (which caused discontinuation of the intervention in 33 patients). The authors state that "it is possible that a longer duration of ECCO2R with greater tidal volume reduction may have been required to demonstrate an effect because higher intensities of invasive MV have been shown to be associated with increased risk of death in a time-dependent fashion". Additional limitations of the study were that (1) only 6% of the screened patients were included in the study, (2) 8% of the randomized subjects in the intervention group did not receive the intervention, and (3) most of the sites had not performed ECLS before the initiation of the study, leading to practical inexperience potentially negatively influencing the outcomes of the intervention group.

The investigators note several differences in their protocol that differentiates it from the REST trial. First, the investigators will use a device capable of obtaining higher blood flow rates with higher initial targets of blood flow (1-2.5L/minute). Specifically, the study will use a low-flow circuit to include the NovaLung system (Fresenius Medical Care, Waltham MA) in conjunction with a smaller tubing set and cannula (15 - 25 Fr versus 23 - 31 for conventional ECMO, as needed) to enable earlier utilization of ECLS with less invasiveness and smaller catheters. Second, the current study includes broader limitations to length of time of the device (e.g. 28 days versus 7 days), which may be a more pragmatic and generalizable approach.

RATIONALE The current standard of care (SOC) for treatment of patients with acute respiratory distress syndrome (ARDS), inhalation injury, volume overload, and/or pulmonary dysfunction is mechanical ventilation (MV). However, these techniques are associated with several complications after prolonged use, including risk of infection, increased sedation requirements, pulmonary edema, ventilator-induced lung injury (VILI), barotrauma, and multi-organ failure. Extracorporeal life support (ECLS) has been used to successfully minimize, replace, or avoid the use of MV. This concept is critical as it permits ultra-lung protective MV settings, mobilization, early ambulation of patients, and timely extubation (when appropriate).

Low-flow ECLS has been shown to prevent deleterious shifts in pH and PaCO2 at a lower level of invasiveness. The investigators hypothesize that the use of low-flow ECLS will be a safe option for the treatment of pulmonary dysfunction and mild and moderate ARDS, that it will significantly reduce MV settings, and that it will decrease the need for intubation for patients requiring respiratory support for either failure to oxygenate or ventilate.

PROCEDURES Subjects meeting criteria for enrollment will be screened by the Principal Investigator or any delegates assigned to review the patient's chart. A HIPAA authorization and informed consent will be provided by the subject or legally authorized representative (LAR) prior to conducting any additional research procedures.

Patients enrolled after consent is obtained will be placed on Low-Flow ECMO by trained physicians. Subjects will be cannulated in one of two ways, either at bedside with the use of radiographic imaging to confirm accurate cannula placement, or in the catheter laboratory under fluoroscopy with safety measures in place to appropriately monitor the patient's vital signs, ventilatory measurements, and LF ECMO settings.

Initiation of LF ECMO will require cannula placement and connection to the Novalung XLung extracorporeal circuit. Size and type of cannula will be determined by the investigator and documented at cannulation. The XLung will be used with circuit to accommodate lower flows necessary to efficiently move 1-2.5 LPM of blood through the oxygenator. Subjects treated with low-flow ECMO will receive systemic anticoagulation per standard of care for patients treated with ECLS. After cannulation and placement on LF ECMO, blood gases will be drawn from the patient, pre-Xlung, and post-Xlung to assess the function of the Novalung system, patient's stability after initiation, and the ability to effectively wean ventilatory support.

Multiple labs will be collected and documented as routine standard of care while others will be collected prior to device implementation and during the duration of therapy for research purposes. The following is considered standard of care (as needed, daily): arterial blood gases, lactate, platelet count. Standard of care costs are billed to insurance. The following are considered research costs (prior to device initiation, within one hour of device initiation [if collected]): arterial blood gases, lactate, platelet count. Heparin doses, aPTT, ACT, anti-Xa, plasma-free hemoglobin, pre- and post-membrane analyses are all research costs, in addition to inflammatory markers and functional outcomes (6MWT, quality of life questionnaires). All research costs are covered by the awarded grant.

Biospecimens: Approximately 2 mLs of blood will be collected in tubes containing EDTA at least seven times (pre-ECLS, daily, post-ECLS, discharge, 30-, 60-, 90-days post-discharge, as available). Blood will be taken prior to the administration of anesthesia (when applicable), from an existing catheter, or by venipuncture. The samples will be placed on ice, and blood will be separated by centrifugation within 30 minutes of collection to yield roughly 1 mL of plasma. The samples will be stored in appropriate freezer (long-term of ≤-80ºC or temporarily ≤-20°C). Urine (up to 10 mLs) will be collected either from the subject's urinary retention catheter or directly from the subject in a urine cup, and it will be stored in appropriate freezer (long-term of ≤ -80ºC or temporarily ≤ -20°C) until analysis.

03

Conditions studied

  • Acute Hypoxemic Respiratory Failure
  • Mechanical Ventilation
  • Acute Respiratory Distress Syndrome (ARDS)

Keywords

  • Extracorporeal Life Support
  • Low-Flow ECLS
  • Mechanical Ventilation
  • Acute Hypoxemic Respiratory Failure
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Acute hypoxemic respiratory failure meeting all the following criteria:

  • New or worsening respiratory symptoms developing within 2 weeks prior to the onset of need for oxygen or respiratory support
  • Endotracheal mechanical ventilation for ≤ 5 days
  • PaO2/FiO2 ≤ 200 mmHg for at least 6 hours, or for at least two readings one hour apart
  • Male or non-pregnant female
  • Admitted to the ICU at MHS
  • Age ≥ 18 years

Exclusion criteria

Exclusion Criteria

  • Hypoxemia is primarily attributable to fluid overload from acute heart failure
  • Hypoxemia is primarily attributable to pulmonary embolism
  • Hypoxemia is primarily attributable to status asthmaticus
  • Extubation is planned or anticipated on the day of screening
  • ICU discharge is planned or anticipated on the day of screening
  • The patient is moribund and deemed unlikely to survive past 24 hours (as determined by the clinical team)
  • The patient has limited code status, ordered for comfort measures only, or is in hospice
  • Patients over 65 years of age
  • Currently receiving any form of ECLS (ex. veno-venous, veno-arterial, or hybrid configuration)
  • ΔPL-dyn ≤ 20 or Static ΔP ≤ 15 cm H2O while receiving VT 6 mL/kg (i.e. normalized elastance \< 2.5 cmH2O/mL/kg)
  • Chronic hypercapnic respiratory failure defined as PaCO2 > 60mmHg in the outpatient setting
  • Home mechanical ventilation (non-invasive ventilation or via tracheotomy), not CPAP
  • Severe hypoxemia with PaO2:FiO2 \< 80mmHg for >6 hours at time of screening
  • Severe hypercapnic respiratory failure with pH \< 7.15 and PaCO2 > 60mmHg for >6 hours at time of screening
  • Expected mechanical ventilation duration \< 48 hours at time of screening
  • Confirmed diffuse alveolar hemorrhage from vasculitis
  • to limited anticoagulation (ex. active GI bleeding, bleeding diathesis)
  • Respiratory failure known or suspected to be caused by COVID-19
  • Cirrhosis of the liver (as classified stage C of the Score)
  • Pregnancy
  • Inability to tolerate extracorporeal therapy (MAP\<65 mmHg despite fluid resuscitation and vasopressors)
  • Unable to obtain from either patient or legally authorized representative (LAR)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Other
    Initiation of low-flow ECLS

    To evaluate the safety, feasibility, and efficacy of low-flow ECLS and assess the feasibility of its use

    Device: Low-flow ECMO

Interventions

  • DeviceLow-flow ECMO

    low-flow ECMO, defined as 1-2.5 L of blood flow/min.

06

What researchers measure

Primary outcomes

  1. Ventilator-free days

    Ventilator-free days in the first 28 days

    Time frame: Documented at 28 Days

Secondary outcomes

  1. Length of Stay (LOS)

    1. LOS in Intensive Care Unit (ICU)

    Time frame: Documented at discharge from the ICU, through study completion (an average of 21 days)

  2. Length of Stay (LOS)

    Length of Stay in Hospital

    Time frame: Documented at discharge from the hospital, through study completion (an average of 21 days)

  3. Mortality

    In-hospital mortality

    Time frame: Documented at occurrence or death, or at discharge from the hospital, through study completion (an average of 21 days)

  4. Duration

    Time to and duration of lung protective settings (Pplat≤ 28 cm H2O \[protective\], Pplat ≤ 25 cm H2O \[ultraprotective level\])

    Time frame: Documented daily throughout hospitalization until discharged, through study completion (an average of 21 days)

  5. Conversion

    Conversion to full ECMO support (\>2.5L/min Flow)

    Time frame: Documented daily throughout hospitalization until discharged, through study completion (an average of 21 days)

  6. Adverse Events

    Serious adverse events (SAEs) and Grade 3 and 4 adverse events (AEs) per Common Terminology Criteria for Adverse Events (CTCAE) v5.0 (November 2017)

    Time frame: Documented at occurrence, or daily at minimum through study completion, through study completion (an average of 21 days)

  7. Anticoagulation

    Anticoagulation (rate); results of clinical coagulation panel collected throughout hospital stay

    Time frame: Documented daily throughout hospitalization until discharged, through study completion (an average of 21 days)

  8. Cardiopulmonary variables: Tidal Volume

    Tidal Volume (ml)

    Time frame: Documented hourly and daily throughout hospitalization until discharged, through study completion (an average of 21 days)

  9. Cardiopulmonary variables: Minute Ventilation

    Minute Ventilation (L/min)

    Time frame: Documented hourly and daily throughout hospitalization until discharged, through study completion (an average of 21 days)

  10. Cardiopulmonary variables: Respiratory Rate

    Respiratory Rate (bpm)

    Time frame: Documented hourly and daily throughout hospitalization until discharged, through study completion (an average of 21 days)

  11. Cardiopulmonary variables: Heart Rate

    Heart Rate (bpm)

    Time frame: Documented hourly and daily throughout hospitalization until discharged, through study completion (an average of 21 days)

  12. Cardiopulmonary variables: Arterial Blood Gas

    Arterial Blood Gas (O2CT, O2Sat, PaO2, PaCO2, pH, HCO3)

    Time frame: Documented as needed for clinical care (typically Q6) throughout hospitalization until discharged, through study completion (an average of 21 days)

  13. Inflammatory Markers

    Inflammatory markers in plasma and in urine

    Time frame: Pre-ECMO, daily on ECMO, at decannulation, and at 30/60/90 day follow-up apointments

07

Study locations

1 site
08

References and documents

Publications

  • Fitzgerald M, Millar J, Blackwood B, Davies A, Brett SJ, McAuley DF, McNamee JJ. Extracorporeal carbon dioxide removal for patients with acute respiratory failure secondary to the acute respiratory distress syndrome: a systematic review. Crit Care. 2014 May 15;18(3):222. doi: 10.1186/cc13875. PubMed 25033302 ↗
  • Bein T, Weber-Carstens S, Goldmann A, Muller T, Staudinger T, Brederlau J, Muellenbach R, Dembinski R, Graf BM, Wewalka M, Philipp A, Wernecke KD, Lubnow M, Slutsky AS. Lower tidal volume strategy ( approximately 3 ml/kg) combined with extracorporeal CO2 removal versus 'conventional' protective ventilation (6 ml/kg) in severe ARDS: the prospective randomized Xtravent-study. Intensive Care Med. 2013 May;39(5):847-56. doi: 10.1007/s00134-012-2787-6. Epub 2013 Jan 10. PubMed 23306584 ↗
  • Schmidt M, Jaber S, Zogheib E, Godet T, Capellier G, Combes A. Feasibility and safety of low-flow extracorporeal CO2 removal managed with a renal replacement platform to enhance lung-protective ventilation of patients with mild-to-moderate ARDS. Crit Care. 2018 May 10;22(1):122. doi: 10.1186/s13054-018-2038-5. PubMed 29743094 ↗
  • Deniau B, Ricard JD, Messika J, Dreyfuss D, Gaudry S. Use of extracorporeal carbon dioxide removal (ECCO2R) in 239 intensive care units: results from a French national survey. Intensive Care Med. 2016 Apr;42(4):624-625. doi: 10.1007/s00134-016-4226-6. Epub 2016 Jan 29. No abstract available. PubMed 26831671 ↗
  • Ruberto F, Bergantino B, Testa MC, D'Arena C, Bernardinetti M, Diso D, De Giacomo T, Venuta F, Pugliese F. Low-flow veno-venous extracorporeal CO2 removal: first clinical experience in lung transplant recipients. Int J Artif Organs. 2014 Dec;37(12):911-7. doi: 10.5301/ijao.5000375. Epub 2015 Jan 13. PubMed 25588765 ↗
  • Habashi NM, Borg UR, Reynolds HN. Low blood flow extracorporeal carbon dioxide removal (ECCO2R): a review of the concept and a case report. Intensive Care Med. 1995 Jul;21(7):594-7. doi: 10.1007/BF01700166. PubMed 7593903 ↗
  • Ki KK, Passmore MR, Chan CHH, Malfertheiner MV, Bouquet M, Cho HJ, Suen JY, Fraser JF. Effect of ex vivo extracorporeal membrane oxygenation flow dynamics on immune response. Perfusion. 2019 Apr;34(1_suppl):5-14. doi: 10.1177/0267659119830012. PubMed 30966901 ↗
  • Terragni PP, Del Sorbo L, Mascia L, Urbino R, Martin EL, Birocco A, Faggiano C, Quintel M, Gattinoni L, Ranieri VM. Tidal volume lower than 6 ml/kg enhances lung protection: role of extracorporeal carbon dioxide removal. Anesthesiology. 2009 Oct;111(4):826-35. doi: 10.1097/ALN.0b013e3181b764d2. PubMed 19741487 ↗
  • Zochios V, Brodie D, Shekar K, Schultz MJ, Parhar KKS. Invasive mechanical ventilation in patients with acute respiratory distress syndrome receiving extracorporeal support: a narrative review of strategies to mitigate lung injury. Anaesthesia. 2022 Oct;77(10):1137-1151. doi: 10.1111/anae.15806. Epub 2022 Jul 21. PubMed 35864561 ↗
  • Needham DM, Colantuoni E, Mendez-Tellez PA, Dinglas VD, Sevransky JE, Dennison Himmelfarb CR, Desai SV, Shanholtz C, Brower RG, Pronovost PJ. Lung protective mechanical ventilation and two year survival in patients with acute lung injury: prospective cohort study. BMJ. 2012 Apr 5;344:e2124. doi: 10.1136/bmj.e2124. PubMed 22491953 ↗
  • McNamee JJ, Gillies MA, Barrett NA, Perkins GD, Tunnicliffe W, Young D, Bentley A, Harrison DA, Brodie D, Boyle AJ, Millar JE, Szakmany T, Bannard-Smith J, Tully RP, Agus A, McDowell C, Jackson C, McAuley DF; REST Investigators. Effect of Lower Tidal Volume Ventilation Facilitated by Extracorporeal Carbon Dioxide Removal vs Standard Care Ventilation on 90-Day Mortality in Patients With Acute Hypoxemic Respiratory Failure: The REST Randomized Clinical Trial. JAMA. 2021 Sep 21;326(11):1013-1023. doi: 10.1001/jama.2021.13374. Erratum In: JAMA. 2022 Jan 4;327(1):86. doi: 10.1001/jama.2021.21948. PubMed 34463700 ↗
  • Combes A, Fanelli V, Pham T, Ranieri VM; European Society of Intensive Care Medicine Trials Group and the "Strategy of Ultra-Protective lung ventilation with Extracorporeal CO2 Removal for New-Onset moderate to severe ARDS" (SUPERNOVA) investigators. Feasibility and safety of extracorporeal CO2 removal to enhance protective ventilation in acute respiratory distress syndrome: the SUPERNOVA study. Intensive Care Med. 2019 May;45(5):592-600. doi: 10.1007/s00134-019-05567-4. Epub 2019 Feb 21. PubMed 30790030 ↗
  • Goligher EC, Tomlinson G, Hajage D, Wijeysundera DN, Fan E, Juni P, Brodie D, Slutsky AS, Combes A. Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome and Posterior Probability of Mortality Benefit in a Post Hoc Bayesian Analysis of a Randomized Clinical Trial. JAMA. 2018 Dec 4;320(21):2251-2259. doi: 10.1001/jama.2018.14276. PubMed 30347031 ↗
  • Combes A, Hajage D, Capellier G, Demoule A, Lavoue S, Guervilly C, Da Silva D, Zafrani L, Tirot P, Veber B, Maury E, Levy B, Cohen Y, Richard C, Kalfon P, Bouadma L, Mehdaoui H, Beduneau G, Lebreton G, Brochard L, Ferguson ND, Fan E, Slutsky AS, Brodie D, Mercat A; EOLIA Trial Group, REVA, and ECMONet. Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome. N Engl J Med. 2018 May 24;378(21):1965-1975. doi: 10.1056/NEJMoa1800385. PubMed 29791822 ↗
  • Peek GJ, Mugford M, Tiruvoipati R, Wilson A, Allen E, Thalanany MM, Hibbert CL, Truesdale A, Clemens F, Cooper N, Firmin RK, Elbourne D; CESAR trial collaboration. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet. 2009 Oct 17;374(9698):1351-63. doi: 10.1016/S0140-6736(09)61069-2. Epub 2009 Sep 15. PubMed 19762075 ↗
  • Ko M, dos Santos PR, Machuca TN, Marseu K, Waddell TK, Keshavjee S, Cypel M. Use of single-cannula venous-venous extracorporeal life support in the management of life-threatening airway obstruction. Ann Thorac Surg. 2015 Mar;99(3):e63-5. doi: 10.1016/j.athoracsur.2014.12.033. PubMed 25742860 ↗
  • Yusuff HO, Zochios V, Vuylsteke A. Extracorporeal membrane oxygenation in acute massive pulmonary embolism: a systematic review. Perfusion. 2015 Nov;30(8):611-6. doi: 10.1177/0267659115583377. Epub 2015 Apr 24. PubMed 25910837 ↗
  • Lamhaut L, Jouffroy R, Soldan M, Phillipe P, Deluze T, Jaffry M, Dagron C, Vivien B, Spaulding C, An K, Carli P. Safety and feasibility of prehospital extra corporeal life support implementation by non-surgeons for out-of-hospital refractory cardiac arrest. Resuscitation. 2013 Nov;84(11):1525-9. doi: 10.1016/j.resuscitation.2013.06.003. Epub 2013 Jul 1. PubMed 23827888 ↗
  • Schmidt M, Hodgson C, Combes A. Extracorporeal gas exchange for acute respiratory failure in adult patients: a systematic review. Crit Care. 2015 Mar 16;19(1):99. doi: 10.1186/s13054-015-0806-z. PubMed 25887146 ↗
  • Gross-Hardt S, Hesselmann F, Arens J, Steinseifer U, Vercaemst L, Windisch W, Brodie D, Karagiannidis C. Low-flow assessment of current ECMO/ECCO2R rotary blood pumps and the potential effect on hemocompatibility. Crit Care. 2019 Nov 6;23(1):348. doi: 10.1186/s13054-019-2622-3. PubMed 31694688 ↗
  • Meyer AD, Rishmawi AR, Kamucheka R, Lafleur C, Batchinsky AI, Mackman N, Cap AP. Effect of blood flow on platelets, leukocytes, and extracellular vesicles in thrombosis of simulated neonatal extracorporeal circulation. J Thromb Haemost. 2020 Feb;18(2):399-410. doi: 10.1111/jth.14661. Epub 2019 Nov 14. PubMed 31628728 ↗
  • Ki KK, Passmore MR, Chan CHH, Malfertheiner MV, Fanning JP, Bouquet M, Millar JE, Fraser JF, Suen JY. Low flow rate alters haemostatic parameters in an ex-vivo extracorporeal membrane oxygenation circuit. Intensive Care Med Exp. 2019 Aug 20;7(1):51. doi: 10.1186/s40635-019-0264-z. PubMed 31432279 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2025; primary completion for Dec 2026, 19 months later.

Of 360 non-industry interventional studies with no phase under Respiratory Insufficiency, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 47. This study's planned 19 months is below that.

Counting every sponsor, half of 376 studies reached it within 24 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2025
First posted
Apr 22, 2025
StartEst.
May 1, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Mar 31, 2027
Last update
Apr 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06938217
Lead sponsor
Institute for Extracorporeal Life Support
Responsible party
Jeffrey DellaVolpe (Medical Director, Institute for Extracorporeal Life Support; Intensivist, Institute for Extracorporeal Life Support) — Principal investigator
First posted
Apr 22, 2025
Start date
May 1, 2025 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Apr 22, 2025

Study contacts

Jeffrey D DellaVolpe, MD, MPH
principal investigator · Institute for Extracorporeal Life Support

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion